Key takeaways
- GLOW is a seller name for a pre-mixed vial of GHK-Cu, BPC-157 and TB-500. It is not a compound or a studied formulation.
- We found no published study, in any species, that tested the mix, and no registered trial of it (PubMed and ClinicalTrials.gov, 18 Nov 2026).
- Each ingredient has its own evidence: small topical skin studies for GHK-Cu, and mostly animal studies for BPC-157 and TB-500.
- HHS’s 2026 interim compounding policy applies only to products with a single active ingredient, so that adverse events can be traced to one substance.
01GHK-Cu and GLOW compared
One compound and one mix that contains it, dated 18 November 2026.
| Question | GHK-Cu | GLOW |
|---|---|---|
| What it is | A single compound: the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine | A seller name for one vial mixing GHK-Cu, BPC-157 and TB-500 |
| Studied as a mix | Not a mix | No study found, in any species |
| Human data | Small topical skin studies; no controlled trial of GHK-Cu given any other way found | None for the mix |
| What a lab report must confirm | One identity and one amount | Three identities and three amounts in one vial |
| HHS interim compounding policy, Oct 2026 | Not on its list | Policy requires a single active ingredient |
Each ingredient has its own page: GHK-Cu, BPC-157 and TB-500.
02What GLOW is
GLOW is a product name, not a molecule. Sellers use it for a single vial that holds three peptides: GHK-Cu, BPC-157 and TB-500. The amount of each peptide is set by whoever fills the vial.
A related seller name, KLOW, lists a fourth peptide, KPV: what is the “KLOW peptide”? The two side by side: GLOW vs KLOW.
The three ingredients are different kinds of molecule:
- GHK-Cu: the copper(II) complex of glycyl-L-histidyl-L-lysine, a tripeptide isolated from human plasma in 1973.
- BPC-157: a synthetic 15-amino-acid peptide.
- TB-500: listed by FDA as “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500”, a seven-amino-acid piece of a larger protein.
03Is there any evidence for GLOW?
Not for the mix. Evidence attaches to what was studied, and we found no published study of this blend.
On 18 November 2026 we searched PubMed for papers naming GHK-Cu (or copper tripeptide, or prezatide) together with BPC-157 (or pentadecapeptide, or Bepecin): 8 results. Adding TB-500 or thymosin beta instead returned 7, all among the same 8. Every one is a review, commentary or letter; none gave the combination to cells, animals or people. ClinicalTrials.gov lists no trial of the mix.
A study of one compound says nothing about a vial in which it shares space with two others. Whether the peptides stay intact together, how much of each is present, and what the mix does are separate questions, and none of the papers we found measured them. The general case is on peptide blends: one vial, no shared evidence.
04What each ingredient has been studied in
Each row is graded on its own. None of it transfers to a mixed vial.
| Ingredient | Main evidence | In people |
|---|---|---|
| GHK-Cu | Cell and animal studies (T4, T3) | Small topical skin studies, mostly conference reports (T2). In the one PubMed-indexed randomised trial of a skin-care regimen, after laser resurfacing, 13 patients completed; objective measures found no difference, though patients rated their skin quality higher. FDA says there are “limited data in humans” for injectable GHK-Cu. |
| BPC-157 | Mostly animal studies (T3) | Small studies, most without a control group (T2); no peer-reviewed randomised trial published (PubMed, 18 Nov 2026). |
| TB-500 | Animal and cell studies (T3, T4) | No controlled human study published; a placebo-controlled trial, NCT07487363, is recruiting. |
The topical GHK-Cu studies used skin products, not a mixed vial: see topical GHK-Cu.
05Why a mixed vial is harder to check and to trace
Testing. A lab report for one peptide confirms one identity and one amount. A blend needs each peptide identified and measured on its own, matched to the batch number. A single purity figure for the whole vial cannot show that each peptide is there, or how much. How to read one: how to read a COA.
Tracing a reaction. FDA’s 2026 review of BPC-157 describes a woman who used a product labelled for research purposes that contained BPC-157 and TB-500 and developed darkening of the skin and gums, which returned when she used it again. FDA staff judged the reactions likely due to the product, but “because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported AEs.” FDA’s TB-500 review found two complaint reports about “blended TB-500 and BPC-157”, without safety assessments.
Compounding. HHS’s interim policy of October 2026 on compounding six peptides, which is not an approval, applies only when the product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”. HHS gives the reason: “It will be easier to attribute adverse events or clinical outcomes to a specific substance.” BPC-157 and TB-500 are on that list; GHK-Cu is not. Background: the HHS peptide policy.
06What we don’t know
- Any effect of GLOW in cells, animals or people. We found no study of the mix.
- Whether the peptides stay intact together in one vial, or change one another. We found no published data.
- Whether findings for GHK-Cu skin products apply to any other route. We found no controlled trial of GHK-Cu given another way.
- What a given vial contains. A lab report shows only what the tested sample from that lot held, and only for the peptides it identifies and measures.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.